Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer
The purpose of this study is to assess the effectiveness of the investigational drug VT-464 in patients with advanced breast cancer. VT0464 works by blocking the androgen receptor and decreasing the production of androgen and estrogen. VT-464 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have either advanced AR-positive triple-negative breast cancer or advanced estrogen receptor-positive breast cancer.
- At least 4 weeks must pass between the completion of prior therapies and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Tiffany A. Traina at 646-888-5209.